彌富 泰佑

精神科医として、臨床の現場・治療に直接繋げることを目指した脳画像研究・基礎研究・薬理疫学研究に取り組んでいます。2025年4月からは横浜市立大学大学院医学研究科生理学教室の方でポスドクとなっております。

Dr. Taisuke Yatomi is a highly productive researcher with a passion to critically reevaluate real clinical practice and therapy in psychiatry and to achieve more precise diagnoses and treatment in patients with mood disorders and schizophrenia (SCZ),  which are among the most difficult diseases to prospect their treatment prognoses, based on neuroimaging, basic research, and pharmacoepidemiology.

To this end, Dr. Yatomi is now eager to conduct how depressive or manic symptoms are emerged with manipulation of the AMPA-R amounts in the frontal regions in mice to provide neurobiological mechanisms in the pathophysiology of mood disorders, based on findings of the results of the human study on the relationship between AMPA-R density and symptoms of mood disorders. He is always attentive to the work his group is doing on animal models of schizophrenia with reduced AMPA receptor density distribution based on the AMPA receptor density distribution in human patients with schizophrenia. In his Ph.D work, he conducted and played a major role in the identification of novel neurobiological targets for therapeutic interventions including pharmacotherapy in psychiatric patients including mood disorders and SCZ with applying relation between α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPA-R) PET and functional Magnetic Resonance Imaging (fMRI). These interests have stemmed from his clinical work as a psychiatrist in Japan. He has been always frustrated with lack of solid, biological evidence regarding pathophysiology underlying psychiatric illnesses, which clearly prevented development of objective diagnostic system and new drug development. At the first step, to tackle the question that steroid-induced symptoms varied patient by patient and to evaluate the circumstances in simultaneous prescription of drugs for mood disorders and physical comorbidities, and to investigate the psychotropic prescriptions in COVID-19 patients after their discharge, I started analysis of the huge database (N=581,990) and the other COVID-19 database (N=52,488), and his work during this period resulted in three publications as a first author in peer-reviewed journals relating to pharmacoepidemiology during this period.

At the same time that these studies were conducted, Dr. Yatomi joined the imaging team in his university and started analysis of PET and fMRI images of psychiatric patients from the start of his Ph.D course. First of all, He has been involved in the study of patients with psychiatric disorders by [11C]K-2 PET (AMPA-R PET) as a core member of the research team. He extracted positive correlation in healthy subjects (HS) between AMPA-R density and intra- and inter- functional centrality derived from functional connectivity with resting-state fMRI (rsfMRI), in the whole brain, many anatomical regions, and many functional networks as his Ph.D work. He is also trying to extract therapeutic mechanism of ketamine to patients with treatment-resistant depression (TRD) using AMPA-R PET and rsfMRI and/or Transcranial Magnetic Stimulation-Electroencephalogram (TMS-EEG) in the ketamine study he has been contributed to.

Overall, his excellent work and achievements have been acknowledged, then he received eight young investigator awards (USD 5,000 in total) and four fellowship awards (USD 48,700 in total), and funded three research grants (USD 28,900 in total). As to his postdoctoral fellowship basic research project, the reason for this project is that it examines if and how depressive and manic symptoms (mood disorders) are emerged with manipulation of the AMPA-R amounts in the targeted brain areas in mice and will likely provide new insights for profounding neurobiological mechanisms in the pathophysiology of mood disorders and novel drug targets for them.

Please check also:

https://x.com/T_Yatomi?t=p4UrhiD1PXMpfgL7SxXC7A&s=06

https://www.linkedin.com/in/taisuke-%E6%B3%B0%E4%BD%91%EF%BC%89-yatomi-%E5%BD%8C%E5%AF%8C-827481236/